Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label single-arm study of Dymista in Chinese adolescents with allergic rhinitis
CTR20260687Phase 4Active
- Sponsor
- Meda
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluticasone propionate in allergic rhinitis (AR), sponsored by Meda. Primary endpoint: Change from baseline in AM + PM reflective total nasal symptom score. Started Jun 2026; status: active.
02
Drugs
fluticasone propionate
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20260687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260687.